CA
NZ
UK
AU
IND
US
Innate Pharma SA (Nasdaq:IPHA)has announced its financial results for the year ending December 31, 2024, alongside notable advancements in its clinical pipeline. The company continues to make progress in immuno-oncology, securing regulatory recognition and funding to support ongoing research efforts.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced significant progress in the development of its proprietary antisense oligonucleotide (ASO) drug candidate, HT-KIT. The biopharmaceutical company is focused on creating therapies for allergic and inflammatory diseases, and HT-KIT represents an innovative approach to treating conditions such …
Entero Therapeutics, Inc. (NASDAQ:ENTO), a clinical-stage biopharmaceutical company specializing in targeted therapies for gastrointestinal diseases, has successfully reached an agreement to rescind its previously completed business combination with ImmunogenX, LLC. The rescission agreement, signed with all former ImmunogenX shareholders, is subject to certain conditions, …
Opthea Limited (NASDAQ:OPT), a clinical-stage biopharmaceutical company, has announced the results of its global Phase 3 COAST (Combination OPT-302 with Aflibercept Study) trial, which evaluated the combination therapy of sozinibercept and aflibercept for the treatment of wet age-related macular degeneration (wet AMD). The trial …
Please wait processing your request...